Clinical trials: Peritoneal (Metastatic) Cancer
Neoplasm, Ovarian, Fallopian Tube Cancer
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
This is an open-label, First-in-Human, Phase 1/2, multicenter study to evaluate the safety and efficacy of a single dose of AVB-001.
- Conditions
- Neoplasm, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenocarcinoma Ovary
- Trial name
- NCT05538624
- Testing
- AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase)
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Avenge Bio, Inc
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This phase II trial tests whether pegylated SN-38 conjugate PLX038 (PLX038) works to shrink tumors in patients with ovarian, primary peritoneal, and fallopian tube cancers that has spread from where it first started (primary…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8
- Trial name
- NCT05465941
- Testing
- Biopsy, Pegylated SN-38 Conjugate PLX038, Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Gastric Adenocarcinoma, Gastric Cancer
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Background: Three-fourths of people diagnosed with gastric cancer will die from it. Researchers want to see if giving cancer drugs in a new way can help people live longer and delay the time it takes for the cancer to grow.
- Conditions
- Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction, Peritoneal Carcinomatosis
- Trial name
- NCT04034251
- Testing
- Paclitaxel, Capecitabine, BardPort Titanium Implanted Port with Peritoneal Catheter
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02898207
- Testing
- Olaparib, Onalespib
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Colorectal Cancer
The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)
This study aims to investigate the value of 18F-FDG and 68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of advanced colorectal cancer (peritoneal metastasis with/without other metastases)
- Trial name
- NCT06601075
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Ventral Hernias, Cytoreductive Surgery
Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management.
Cytoreductive surgery (CRS), with or without hyperthermic intraperitoneal chemotherapy (HIPEC), is currently the standard treatment for advanced peritoneal tumors, including pseudomyxoma peritonei (PMP), colorectal, and ovarian…
- Trial name
- NCT07451483
- Where
- Belgium
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Jules Bordet Institute
Peritoneal Carcinomatosis
Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis
The study would examine by hypericin-supported Fluoreszenzlaparoskopy in terms of tumor size, number and location of the combination of photodynamic diagnosis (PDD) and therapy (PDT) with regard to the detection of peritoneal…
- Trial name
- Hypericin-PDT (NCT02840331)
- Testing
- St. John's Wort, Photodynamic diagnostic and therapy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Tuebingen
This Study Uses AI and Multimodal Data to Noninvasively Detect Occult Peritoneal Metastasis
Prediction of Occult Peritoneal Metastasis of Locally Advanced Gastric Cancer Using Multimodal Data Based on Artificial Intelligence Combined With Intraoperative Dynamic Video
Brief Summary: Prediction of Occult Peritoneal Metastasis of Locally Advanced Gastric Cancer Using Multimodal Data Based on Artificial Intelligence Combined with Intraoperative Dynamic Video Gastric cancer, or stomach cancer, is…
- Trial name
- NCT06478368
- Testing
- Laparoscopic exploration
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Qun Zhao
Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer
FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)
The goal of this clinical trial is to test whether adding targeted radiation plus cadonilimab immunotherapy to standard second-line chemo works better for adults with colorectal cancer only spread to the peritoneum, and check how…
- Conditions
- Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer, Second-line Treatment, Radiation Therapy
- Trial name
- TORCH-PM02 (NCT07815834)
- Testing
- Second-Line Chemotherapy, Radiation Therapy, Cadonilimab (AK104)
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Fudan University
Gastric Cancer Peritoneal Metastases
Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis
The most common site for gastric cancer distant metastases is the peritoneum. Median survival for this group of patients is short and systemic cytotoxic treatment response is poor, partly due to the low uptake of the treatment…
- Trial name
- IPa-Gastric (NCT07304271)
- Testing
- Intraperitoneal Paclitaxel, Standard systemic therapy
- Where
- 7 sites in Italy, Netherlands and 1 more
- Volunteers
- 262 people
- Sponsor
- Magnus Nilsson
Peritoneal Carcinomatosis, Appendiceal Neoplasms
Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)
The goal of this prospective phase II unicentric Canadian clinical trial is to clarify the feasibility of modified early post-operative intraperitoneal chemotherapy (mEPIC) following cytoreductive surgery (CRS) and hyperthermic…
- Conditions
- Peritoneal Carcinomatosis, Appendiceal Neoplasms, Colorectal Cancer Metastatic
- Trial name
- NCT05913674
- Testing
- Modified early post-operative intraperitoneal chemotherapy (mEPIC)
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Peritoneal Carcinomatosis, Peritoneal Metastases From Colorectal Cancer
Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.
Colorectal cancer is highly prevalent in France, ranking second among women and third among men. Its primary metastatic sites include the liver, lungs, and peritoneum.
- Trial name
- NUCLEAR (NCT06929013)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 58 people
- Sponsor
- Hospices Civils de Lyon
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
This clinical trial studies if enhanced outpatient symptom management with telemedicine and remote monitoring can help reduce acute care visit due to chemotherapy-related adverse events.
- Conditions
- Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT05038254
- Testing
- Best Practice, Patient Monitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer
Biomarker Analysis of HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With Peritoneal Metastasis
A single-center, observational study, integrated biomarker analysis of HIPEC combined Programmed cell death 1 /Programmed cell death 1 ligand 1(PD1/PDL1)inhibitor in previously treated patients of advanced gastric cancer with…
- Trial name
- NCT05661110
- Testing
- Observational
- Volunteers
- 46 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Colorectal Cancer, Metastatic Cancer
Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Metastatic Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005944
- Testing
- chemotherapy, fluorouracil, leucovorin calcium
- Where
- 18 sites in Belgium, France
- Sponsor
- UNICANCER
Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
Durvalumab and Tremelimumab in combination with first-line chemotherapy in the following indications: Ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC and gastric/GEJ cancer, PDAC, ESCC.
- Conditions
- Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms
- Trial name
- NCT02658214
- Testing
- paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin
- Where
- 6 sites in Japan, South Korea
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Gastric Cancer Peritoneal Metastases
A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
This study aims to evaluate the efficacy and safety of HIPEC combined with NIPS and tislelizumab conversion therapy for gastric/gastroesophageal junction cancer with positive cytology alone (CY1P0) or a Peritoneal Carcinomatosis…
- Trial name
- NCT07304258
- Testing
- HIPEC, NIPS, Paclitaxel Injection, S-1, tislelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hebei Medical University
Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer
LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
In this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.
- Conditions
- Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer, Gastric or Esophagogastric Junction Adenocarcinoma
- Trial name
- NCT07556640
- Testing
- LM-302, S-1, paclitaxel, LM-302, Cadonilimab, S-1, paclitaxel
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Ruijin Hospital
Ovarian Cancer, Ovarian Neoplasms
EDMONd - Elemental Diet in Bowel Obstruction
A feasibility study to provide 'proof of concept' of Elemental Diet (ED) as an acceptable/ useful feeding option for patient with inoperable malignant bowel obstruction and to examine the impact of ED on quality of life
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Disease, Peritoneal Neoplasms
- Trial name
- EDMONd (NCT03150992)
- Testing
- Elemental 028 Extra Liquid
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust